Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Key Highlights
- ➤ICOTYDE (JNJ) sustained clear or almost clear skin in 70% at Week 112
- ➤60% of scalp psoriasis patients achieved complete scalp clearance at Week 112
- ➤89% of genital psoriasis patients achieved complete genital clearance at Week 112
- ➤63% of hand and/or foot psoriasis patients achieved complete clearance at Week 112
- ➤No new safety signals identified through Week 112
Expert Statements
Richard B. Warren, Professor of Dermatology, University of Manchester
“These robust two-year data validate that ICOTYDE provides enduring skin clearance with a favorable safety profile, making it a pivotal advancement in plaque psoriasis treatment.”
David M. Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson
“These two-year ICOTYDE results empower physicians to treat high-impact sites, knowing that data support sustained clinical outcomes for patients.”
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy PR Newswire
* Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body * 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112 SPRING HOUSE, Pa., Oct. 2, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTAL(a) study demonstrating the positive impact of ICOTYDE(®) (icotrokinra) on high-impact plaque psoriasis (PsO) sites. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor(1), in adults and pediatric patients 12 years of age and older (adolescents).
Get started
Create a free account to read the full story.